15
Dosing Frequency Comments
†
Once daily • Oral agents
• First-line therapy for ASCVD risk reduction in nearly all patients
• Extensive CVOT evidence demonstrates reductions in events over
wide range of LDL-C levels in primary and secondary prevention
• Expected LDL-C reduction: 18%–55%
‡
• Atorvastatin and rosuvastatin can achieve high-intensity
LDL-C reductions and are preferred for patients at high/very
high ASCVD risk
• Atorvastatin, pitavastatin, and rosuvastatin have long half-lives
that enable dosing any time of the day
Once or twice daily
Once or twice daily
Once daily
Once daily
Once daily
Once daily
Once daily • Oral agent
• CVOT evidence demonstrates reductions in cardiovascular
events in very high-risk secondary prevention in combination
with a moderate-intensity statin therapy
• Expected LDL-C reduction: monotherapy, 18%; combination
with a statin, 25% incremental reduction
‡
• Drug of choice in sitosterolemia to reduce elevated sitosterol
and campesterol
Every 2 weeks
Every 4 weeks
• Subcutaneous agents
• CVOT evidence demonstrates reductions in cardiovascular
events in very high-risk secondary prevention in combination
with a maximally tolerated statin therapy
• Expected LDL-C reduction: 45%–64%
‡
• Lower mean LDL-C reduction (21%–31%) in homozygous
FH due to LDLR gene variants
Every 2 weeks
Once daily • Oral agent
• CVOT evidence demonstrating reductions in cardiovascular
events in individuals treated for high-risk primary and
secondary prevention with statin-attributed side effects
• Prodrug that is activated by very long-chain acyl-CoA
synthetase, found primarily in the liver
• Expected LDL-C reduction: monotherapy in patients with
statin-attributed side effects, 21%–24% combination with a
statin, 17%–18%
‡
